Abbott wins FDA nod for insertable cardiac monitor Assert-IQ
Tim Boyle
Abbott Laboratories (NYSE:ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) cleared its Assert-IQ insertable cardiac monitor, a device to detect irregular heartbeats.
Assert-IQ is available in two options with a battery life of at least three or six years, and according to Abbott (ABT), the device offers the world's longest battery life for an insertable cardiac monitor.
Three-year option is more suitable for traditional cardiac monitoring in the events such as fainting and heart palpitations. The option for at least six years of battery life will be preferable for long-term monitoring.
Assert-IQ is connected through Bluetooth technology and allows clinicians to conduct real-time monitoring of heart rhythms, usually via a person's cell phone.
“Abbott's Assert-IQ ICM offers physicians a connected health device that will help them provide the best care for their patients while making more accurate and informed treatment decisions,” remarked Leonard Ganz, chief medical officer of Abbott's cardiac rhythm management business.